ASCA Corporation and ProductLife Japan are jointly hosting a webinar titled "Ensuring Success in the Pharmaceutical Business After EMA Approval: A Perspective on Market and Patient Access -"
The webinar will feature Mr. Alberto Rubio, VP Executive Partner, Market & Patient Access at ProductLife Group.
For Japanese pharmaceutical companies, EMA approval does not guarantee success in the European market. The real challenge lies in addressing first the evidence requirements at EU level as a result of the implementation of the EU HTA regulation, commonly referred as JCA (Joint Clinical Assessment). Additionally, the subsequent drug pricing and reimbursement strategies in each country, will call for bespoke value proposition with payers, penetration into physicians' prescribing behaviors, ensuring patient access, optimizing sales channels, and managing commercialization risks.
This webinar will draw on extensive practical expertise to offer insights on how to navigate these complex requirements after EMA approval and successfully build a business in the European market.
※Note: The presentation portion will be in English; pre-submitted questions will be answered in Japanese and English. An AI interpretation system will be available for real-time attendees, though this does not apply to recorded viewing. The accuracy of the AI interpretation system's translations is not guaranteed.
| Speaker Profiles | |
 | Speaker |
Mr. Alberto Rubio VP Executive Partner Market & Patient Access | |
 | Q&A Facilitator |
Mr. Tadao Tsuchida Director, Business Development-Japan | |
Date: 29th (Tue) on September, 05:00-06:00 PM/JST (10:00-11:00 AM/GMT+2)
Onlien（Zoom Webianr）
(Opens an external site)
About Product Life Group
.png)
ProductLife Japan K.K. delivers regulatory affairs, quality, safety, and compliance consulting, supporting pharmaceutical, biotech, and medical device companies across Japan throughout the full product lifecycle from development to post-marketing activities.
About ASCA Corporation
ASCA Corporation provides translation and writing documentation services specialized in the pharmaceutical industry. It has developed an AI translation engine specialized in medicine and pharmaceuticals and sells the AI translation platform "AIKO SciLingual." Through fast, high-precision pharmaceutical translation leveraging generative AI—including significant turnaround time reductions—ASCA supports efforts to resolve drug lag and drug loss.
ASCA Corporation - ASCA Corporation
About "LiveTrasnaltion"
Live Translation requires no dedicated app; participants simply scan a QR code to view translated text and hear audio in 46 languages on their own smartphones. Compared to arranging simultaneous interpreters, it significantly reduces preparation effort and cost. A roughly 45-minute online demo is available to explain usage scenarios and pricing for conferences with overseas speakers or briefings for international investors and partners.
Flitto Live Translation | Flitto Japan | 全世界1,030万のクラウドソーシング翻訳プラットフォーム
対象者
Target Audience: Professionals in Medical Affairs, Market Access, Patient Support, Medical Information, Business Development, and Marketing departments at pharmaceutical companies, startups, and CROs
※Note: Attendance by staff of translation companies or consulting firms is not permitted.
Participation Fee
Free
Capacity
500 (advance registration required; first-come, first-served)
Organizer
ASCA Corporation
Co-host: ProductLife Japan K.K.
Contact
ASCA Corporation: contact page
ProductLife Japan: contact page
Webinar contact: Yoshiyuki Furuya, Sales Department, ASCA Corporation — yoshiyuki.furuya@asca-co.com
